Mechanistic Insights of Vitamin D Anticancer Effects

Vitamins and Hormones

Volumn 100, Issue , 2016, Pages 395-431

  Ma, Yingyu ^a   Johnson, Candace S ^a   Trump, Donald L ^a,b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b Inova Dwight and Martha Schar Cancer Institute   (United States)

Author keywords

1,25D3; Apoptosis; Cancer; Chemotherapy; Differentiation; Inflammation; Metastasis; Prevention; Vitamin D

Indexed keywords

ANTINEOPLASTIC AGENT; VITAMIN D;

ANIMAL; CELL PROLIFERATION; DRUG EFFECTS; HUMAN; NEOPLASMS; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; CELL LINE, TUMOR; CELL PROLIFERATION; HUMANS; NEOPLASMS; VITAMIN D;

EID: 84969916132     PISSN: 00836729     EISSN: None     Source Type: Book Series    
DOI: 10.1016/bs.vh.2015.11.003     Document Type: Chapter

References (192)

1. Abe E., Miyaura C., Sakagami H., Takeda M., Konno K., Yamazaki T., et al. Differentiation of mouse myeloid leukemia cells induced by 1 alpha,25-dihydroxyvitamin D3. Proceedings of the National Academy of Sciences of the United States of America 1981, 78(8):4990-4994. Epub 1981/08/01.
2. Adams J.S., Hewison M. Unexpected actions of vitamin D: New perspectives on the regulation of innate and adaptive immunity. Nature Clinical Practice. Endocrinology & Metabolism 2008, 4(2):80-90. Epub 2008/01/24.
3. Ahn J., Peters U., Albanes D., Purdue M.P., Abnet C.C., Chatterjee N., et al. Serum vitamin D concentration and prostate cancer risk: A nested case-control study. Journal of the National Cancer Institute 2008, 100(11):796-804. Epub 2008/05/29.
4. Ajibade A.A., Kirk J.S., Karasik E., Gillard B., Moser M.T., Johnson C.S., et al. Early growth inhibition is followed by increased metastatic disease with vitamin D (calcitriol) treatment in the TRAMP model of prostate cancer. PLoS One 2014, 9(2):e89555. Epub 2014/03/04.
5. Albert D.M., Scheef E.A., Wang S., Mehraein F., Darjatmoko S.R., Sorenson C.M., et al. Calcitriol is a potent inhibitor of retinal neovascularization. Investigative Ophthalmology & Visual Science 2007, 48(5):2327-2334.
6. Alvarez-Diaz S., Valle N., Ferrer-Mayorga G., Lombardia L., Herrera M., Dominguez O., et al. MicroRNA-22 is induced by vitamin D and contributes to its antiproliferative, antimigratory and gene regulatory effects in colon cancer cells. Human Molecular Genetics 2012, 21(10):2157-2165. Epub 2012/02/14.
7. Amaral A.F., Mendez-Pertuz M., Munoz A., Silverman D.T., Allory Y., Kogevinas M., et al. Plasma 25-hydroxyvitamin D3 and bladder cancer risk according to tumor stage and FGFR3 status: A mechanism-based epidemiological study. Journal of the National Cancer Institute 2012, 104(24):1897-1904. Epub 2012/10/31.
8. Atsumi T., Singh R., Sabharwal L., Bando H., Meng J., Arima Y., et al. Inflammation amplifier, a new paradigm in cancer biology. Cancer Research 2014, 74(1):8-14. Epub 2013/12/24.
9. Bao B.Y., Yao J., Lee Y.F. 1Alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis. Carcinogenesis 2006, 27(9):1883-1893.
10. Bao B.Y., Yeh S.D., Lee Y.F. 1Alpha,25-dihydroxyvitamin D3 inhibits prostate cancer cell invasion via modulation of selective proteases. Carcinogenesis 2006, 27(1):32-42.
11. Beer T.M., Garzotto M., Park B., Mori M., Myrthue A., Janeba N., et al. Effect of calcitriol on prostate-specific antigen in vitro and in humans. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2006, 12(9):2812-2816. Epub 2006/05/06.
12. Bernardi R.J., Johnson C.S., Modzelewski R.A., Trump D.L. Antiproliferative effects of 1alpha,25-dihydroxyvitamin D(3) and vitamin D analogs on tumor-derived endothelial cells. Endocrinology 2002, 143(7):2508-2514.
13. Bernardi R.J., Trump D.L., Yu W.D., McGuire T.F., Hershberger P.A., Johnson C.S. Combination of 1alpha,25-dihydroxyvitamin D(3) with dexamethasone enhances cell cycle arrest and apoptosis: Role of nuclear receptor cross-talk and Erk/Akt signaling. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2001, 7(12):4164-4173.
14. Bertone-Johnson E.R., Chen W.Y., Holick M.F., Hollis B.W., Colditz G.A., Willett W.C., et al. Plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D and risk of breast cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2005, 14(8):1991-1997. Epub 2005/08/17.
15. Bhatia V., Saini M.K., Shen X., Bi L.X., Qiu S., Weigel N.L., et al. EB1089 inhibits the parathyroid hormone-related protein-enhanced bone metastasis and xenograft growth of human prostate cancer cells. Molecular Cancer Therapeutics 2009, 8(7):1787-1798.
16. Bolland M.J., Grey A., Gamble G.D., Reid I.R. Calcium and vitamin D supplements and health outcomes: A reanalysis of the Women's Health Initiative (WHI) limited-access data set. The American Journal of Clinical Nutrition 2011, 94(4):1144-1149. Epub 2011/09/02.
17. Boscoe F.P., Schymura M.J. Solar ultraviolet-B exposure and cancer incidence and mortality in the United States, 1993-2002. BMC Cancer 2006, 6:264. Epub 2006/11/14.
18. Bothwell K.D., Shaurova T., Merzianu M., Suresh A., Kuriakose M.A., Johnson C.S., et al. Impact of short-term 1,25-dihydroxyvitamin D3 on the chemopreventive efficacy of erlotinib against oral cancer. Cancer Prevention Research (Philadelphia, PA) 2015, 8(9):765-776. Epub 2015/06/24.
19. Boyle B.J., Zhao X.Y., Cohen P., Feldman D. Insulin-like growth factor binding protein-3 mediates 1 alpha,25-dihydroxyvitamin d(3) growth inhibition in the LNCaP prostate cancer cell line through p21/WAF1. The Journal of Urology 2001, 165(4):1319-1324. Epub 2001/03/21.
20. Brackman D., Lund-Johansen F., Aarskog D. Expression of cell surface antigens during the differentiation of HL-60 cells induced by 1,25-dihydroxyvitamin D3, retinoic acid and DMSO. Leukemia Research 1995, 19(1):57-64. Epub 1995/01/01.
21. Callens C., Coulon S., Naudin J., Radford-Weiss I., Boissel N., Raffoux E., et al. Targeting iron homeostasis induces cellular differentiation and synergizes with differentiating agents in acute myeloid leukemia. The Journal of Experimental Medicine 2010, 207(4):731-750.
22. Capiati D.A., Rossi A.M., Picotto G., Benassati S., Boland R.L. Inhibition of serum-stimulated mitogen activated protein kinase by 1alpha,25(OH)2-vitamin D3 in MCF-7 breast cancer cells. Journal of Cellular Biochemistry 2004, 93(2):384-397. Epub 2004/09/16.
23. Chaudhry M., Sundaram S., Gennings C., Carter H., Gewirtz D.A. The vitamin D3 analog, ILX-23-7553, enhances the response to adriamycin and irradiation in MCF-7 breast tumor cells. Cancer Chemotherapy and Pharmacology 2001, 47(5):429-436.
24. Chen A., Davis B.H., Bissonnette M., Scaglione-Sewell B., Brasitus T.A. 1,25-Dihydroxyvitamin D(3) stimulates activator protein-1-dependent Caco-2 cell differentiation. The Journal of Biological Chemistry 1999, 274(50):35505-35513. Epub 1999/12/10.
25. Chiang K.C., Yeh C.N., Hsu J.T., Jan Y.Y., Chen L.W., Kuo S.F., et al. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells. Cancer Letters 2014, 354(2):235-244. Epub 2014/08/26.
26. Cho Y.L., Christensen C., Saunders D.E., Lawrence W.D., Deppe G., Malviya V.K., et al. Combined effects of 1,25-dihydroxyvitamin D3 and platinum drugs on the growth of MCF-7 cells. Cancer Research 1991, 51(11):2848-2853.
27. Chung I., Han G., Seshadri M., Gillard B.M., Yu W.D., Foster B.A., et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo. Cancer Research 2009, 69(3):967-975.
28. Chung I., Karpf A.R., Muindi J.R., Conroy J.M., Nowak N.J., Johnson C.S., et al. Epigenetic silencing of CYP24 in tumor-derived endothelial cells contributes to selective growth inhibition by calcitriol. The Journal of Biological Chemistry 2007, 282(12):8704-8714.
29. Chung I., Wong M.K., Flynn G., Yu W.D., Johnson C.S., Trump D.L. Differential antiproliferative effects of calcitriol on tumor-derived and matrigel-derived endothelial cells. Cancer Research 2006, 66(17):8565-8573.
30. Cicarma E., Tuorkey M., Juzeniene A., Ma L.W., Moan J. Calcitriol treatment improves methyl aminolaevulinate-based photodynamic therapy in human squamous cell carcinoma A431 cells. The British Journal of Dermatology 2009, 161(2):413-418.
31. Clark C.S., Konyer J.E., Meckling K.A. 1Alpha,25-dihydroxyvitamin D3 and bryostatin-1 synergize to induce monocytic differentiation of NB4 acute promyelocytic leukemia cells by modulating cell cycle progression. Experimental Cell Research 2004, 294(1):301-311.
32. Clinckspoor I., Verlinden L., Overbergh L., Korch C., Bouillon R., Mathieu C., et al. 1,25-Dihydroxyvitamin D3 and a superagonistic analog in combination with paclitaxel or suberoylanilide hydroxamic acid have potent antiproliferative effects on anaplastic thyroid cancer. The Journal of Steroid Biochemistry and Molecular Biology 2011, 124(1-2):1-9. Epub 2010/12/25.
33. Colston K.W., Perks C.M., Xie S.P., Holly J.M. Growth inhibition of both MCF-7 and Hs578T human breast cancer cell lines by vitamin D analogues is associated with increased expression of insulin-like growth factor binding protein-3. Journal of Molecular Endocrinology 1998, 20(1):157-162. Epub 1998/03/26.
34. Dackiw A.P., Ezzat S., Huang P., Liu W., Asa S.L. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004, 145(12):5840-5846. Epub 2004/08/21.
35. Danilenko M., Wang Q., Wang X., Levy J., Sharoni Y., Studzinski G.P. Carnosic acid potentiates the antioxidant and prodifferentiation effects of 1alpha,25-dihydroxyvitamin D3 in leukemia cells but does not promote elevation of basal levels of intracellular calcium. Cancer Research 2003, 63(6):1325-1332.
36. Deeb K.K., Trump D.L., Johnson C.S. Vitamin D signalling pathways in cancer: Potential for anticancer therapeutics. Nature Reviews. Cancer 2007, 7(9):684-700.
37. De Haes P., Garmyn M., Degreef H., Vantieghem K., Bouillon R., Segaert S. 1,25-Dihydroxyvitamin D3 inhibits ultraviolet B-induced apoptosis, Jun kinase activation, and interleukin-6 production in primary human keratinocytes. Journal of Cellular Biochemistry 2003, 89(4):663-673.
38. Demasters G., Di X., Newsham I., Shiu R., Gewirtz D.A. Potentiation of radiation sensitivity in breast tumor cells by the vitamin D3 analogue, EB 1089, through promotion of autophagy and interference with proliferative recovery. Molecular Cancer Therapeutics 2006, 5(11):2786-2797. Epub 2006/11/24.
39. Diakos C.I., Charles K.A., McMillan D.C., Clarke S.J. Cancer-related inflammation and treatment effectiveness. The Lancet Oncology 2014, 15(11):e493-e503. Epub 2014/10/05.
40. Diaz G.D., Paraskeva C., Thomas M.G., Binderup L., Hague A. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells: Possible implications for prevention and therapy. Cancer Research 2000, 60(8):2304-2312.
41. Ding E.L., Mehta S., Fawzi W.W., Giovannucci E.L. Interaction of estrogen therapy with calcium and vitamin D supplementation on colorectal cancer risk: Reanalysis of Women's Health Initiative randomized trial. International Journal of Cancer 2008, 122(8):1690-1694. Epub 2007/12/20.
42. Dunlap N., Schwartz G.G., Eads D., Cramer S.D., Sherk A.B., John V., et al. 1Alpha,25-dihydroxyvitamin D(3) (calcitriol) and its analogue, 19-nor-1alpha,25(OH)(2)D(2), potentiate the effects of ionising radiation on human prostate cancer cells. British Journal of Cancer 2003, 89(4):746-753.
43. Duque G., El Abdaimi K., Henderson J.E., Lomri A., Kremer R. Vitamin D inhibits Fas ligand-induced apoptosis in human osteoblasts by regulating components of both the mitochondrial and Fas-related pathways. Bone 2004, 35(1):57-64.
44. El Abdaimi K., Dion N., Papavasiliou V., Cardinal P.E., Binderup L., Goltzman D., et al. The vitamin D analogue EB 1089 prevents skeletal metastasis and prolongs survival time in nude mice transplanted with human breast cancer cells. Cancer Research 2000, 60(16):4412-4418.
45. Elstner E., Linker-Israeli M., Le J., Umiel T., Michl P., Said J.W., et al. Synergistic decrease of clonal proliferation, induction of differentiation, and apoptosis of acute promyelocytic leukemia cells after combined treatment with novel 20-epi vitamin D3 analogs and 9-cis retinoic acid. The Journal of Clinical Investigation 1997, 99(2):349-360.
46. Elstner E., Linker-Israeli M., Umiel T., Le J., Grillier I., Said J., et al. Combination of a potent 20-epi-vitamin D3 analogue (KH 1060) with 9-cis-retinoic acid irreversibly inhibits clonal growth, decreases bcl-2 expression, and induces apoptosis in HL-60 leukemic cells. Cancer Research 1996, 56(15):3570-3576.
47. Ferrero D., Campa E., Dellacasa C., Campana S., Foli C., Boccadoro M. Differentiating agents+low-dose chemotherapy in the management of old/poor prognosis patients with acute myeloid leukemia or myelodysplastic syndrome. Haematologica 2004, 89(5):619-620.
48. Folkman J. Tumor angiogenesis: Therapeutic implications. The New England Journal of Medicine 1971, 285(21):1182-1186.
49. Fujioka T., Hasegawa M., Ishikura K., Matsushita Y., Sato M., Tanji S. Inhibition of tumor growth and angiogenesis by vitamin D3 agents in murine renal cell carcinoma. The Journal of Urology 1998, 160(1):247-251.
50. Funato K., Miyazawa K., Yaguchi M., Gotoh A., Ohyashiki K. Combination of 22-oxa-1,25-dihydroxyvitamin D(3), a vitamin D(3) derivative, with vitamin K(2) (VK2) synergistically enhances cell differentiation but suppresses VK2-inducing apoptosis in HL-60 cells. Leukemia 2002, 16(8):1519-1527.
51. Gagliani N., Hu B., Huber S., Elinav E., Flavell R.A. The fire within: Microbes inflame tumors. Cell 2014, 157(4):776-783. Epub 2014/05/13.
52. Garland C.F., Comstock G.W., Garland F.C., Helsing K.J., Shaw E.K., Gorham E.D. Serum 25-hydroxyvitamin D and colon cancer: Eight-year prospective study. Lancet 1989, 2(8673):1176-1178. Epub 1989/11/18.
53. Garland C.F., Garland F.C. Do sunlight and vitamin D reduce the likelihood of colon cancer?. International Journal of Epidemiology 1980, 9(3):227-231. Epub 1980/09/01.
54. Garland C.F., Garland F.C., Gorham E.D., Lipkin M., Newmark H., Mohr S.B., et al. The role of vitamin D in cancer prevention. American Journal of Public Health 2006, 96(2):252-261.
55. Garland C.F., Gorham E.D., Mohr S.B., Garland F.C. Vitamin D for cancer prevention: Global perspective. Annals of Epidemiology 2009, 19(7):468-483. Epub 2009/06/16.
56. Gavrilov V., Steiner M., Shany S. The combined treatment of 1,25-dihydroxyvitamin D3 and a non-steroid anti-inflammatory drug is highly effective in suppressing prostate cancer cell line (LNCaP) growth. Anticancer Research 2005, 25(5):3425-3429.
57. Giovannucci E. Vitamin D, and cancer incidence in the Harvard cohorts. Annals of Epidemiology 2009, 19(2):84-88.
58. Giovannucci E., Liu Y., Rimm E.B., Hollis B.W., Fuchs C.S., Stampfer M.J., et al. Prospective study of predictors of vitamin D status and cancer incidence and mortality in men. Journal of the National Cancer Institute 2006, 98(7):451-459.
59. Giovannucci E., Liu Y., Stampfer M.J., Willett W.C. A prospective study of calcium intake and incident and fatal prostate cancer. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2006, 15(2):203-210.
60. Gonzalez-Pardo V., D'Elia N., Verstuyf A., Boland R., Russo de Boland A. NFkappaB pathway is down-regulated by 1alpha,25(OH)(2)-vitamin D(3) in endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein coupled receptor. Steroids 2012, 77(11):1025-1032. Epub 2012/06/12.
61. Gonzalez-Pardo V., Martin D., Gutkind J.S., Verstuyf A., Bouillon R., de Boland A.R., et al. 1 Alpha,25-dihydroxyvitamin D3 and its TX527 analog inhibit the growth of endothelial cells transformed by Kaposi sarcoma-associated herpes virus G protein-coupled receptor in vitro and in vivo. Endocrinology 2010, 151(1):23-31. Epub 2009/11/17.
62. Grant W.B. An estimate of premature cancer mortality in the U.S. due to inadequate doses of solar ultraviolet-B radiation. Cancer 2002, 94(6):1867-1875. Epub 2002/03/29.
63. Grant W.B. An ecologic study of cancer mortality rates in Spain with respect to indices of solar UVB irradiance and smoking. International Journal of Cancer 2007, 120(5):1123-1128. Epub 2006/12/07.
64. Grant W.B., Garland C.F. The association of solar ultraviolet B (UVB) with reducing risk of cancer: Multifactorial ecologic analysis of geographic variation in age-adjusted cancer mortality rates. Anticancer Research 2006, 26(4A):2687-2699. Epub 2006/08/05.
65. Grundmann M., Haidar M., Placzko S., Niendorf R., Darashchonak N., Hubel C.A., et al. Vitamin D improves the angiogenic properties of endothelial progenitor cells. American Journal of Physiology. Cell Physiology 2012, 303(9):C954-C962. Epub 2012/08/31.
66. Guan H., Liu C., Chen Z., Wang L., Li C., Zhao J., et al. 1,25-Dihydroxyvitamin D3 up-regulates expression of hsa-let-7a-2 through the interaction of VDR/VDRE in human lung cancer A549 cells. Gene 2013, 522(2):142-146. Epub 2013/04/10.
67. Guzey M., Kitada S., Reed J.C. Apoptosis induction by 1alpha,25-dihydroxyvitamin D3 in prostate cancer. Molecular Cancer Therapeutics 2002, 1(9):667-677.
68. Hanahan D., Weinberg R.A. Hallmarks of cancer: The next generation. Cell 2011, 144(5):646-674. Epub 2011/03/08.
69. Haselberger M., Springwald A., Konwisorz A., Lattrich C., Goerse R., Ortmann O., et al. Silencing of the icb-1 gene inhibits the induction of differentiation-associated genes by vitamin D3 and all-trans retinoic acid in gynecological cancer cells. International Journal of Molecular Medicine 2011, 28(1):121-127. Epub 2011/04/02.
70. Hawk E.T., Viner J.L., Dannenberg A., DuBois R.N. COX-2 in cancer-A player that's defining the rules. Journal of the National Cancer Institute 2002, 94(8):545-546. Epub 2002/04/18.
71. Hershberger P.A., McGuire T.F., Yu W.D., Zuhowski E.G., Schellens J.H., Egorin M.J., et al. Cisplatin potentiates 1,25-dihydroxyvitamin D3-induced apoptosis in association with increased mitogen-activated protein kinase kinase kinase 1 (MEKK-1) expression. Molecular Cancer Therapeutics 2002, 1(10):821-829.
72. Hershberger P.A., Modzelewski R.A., Shurin Z.R., Rueger R.M., Trump D.L., Johnson C.S. 1,25-Dihydroxycholecalciferol (1,25-D3) inhibits the growth of squamous cell carcinoma and down-modulates p21(Waf1/Cip1) in vitro and in vivo. Cancer Research 1999, 59(11):2644-2649.
73. Hershberger P.A., Yu W.D., Modzelewski R.A., Rueger R.M., Johnson C.S., Trump D.L. Calcitriol (1,25-dihydroxycholecalciferol) enhances paclitaxel antitumor activity in vitro and in vivo and accelerates paclitaxel-induced apoptosis. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 2001, 7(4):1043-1051.
74. Hidalgo A.A., Deeb K.K., Pike J.W., Johnson C.S., Trump D.L. Dexamethasone enhances 1alpha,25-dihydroxyvitamin D3 effects by increasing vitamin D receptor transcription. The Journal of Biological Chemistry 2011, 286(42):36228-36237.
75. Hmama Z., Nandan D., Sly L., Knutson K.L., Herrera-Velit P., Reiner N.E. 1Alpha,25-dihydroxyvitamin D(3)-induced myeloid cell differentiation is regulated by a vitamin D receptor-phosphatidylinositol 3-kinase signaling complex. The Journal of Experimental Medicine 1999, 190(11):1583-1594. Epub 1999/12/10.
76. Hoyer-Hansen M., Bastholm L., Mathiasen I.S., Elling F., Jaattela M. Vitamin D analog EB1089 triggers dramatic lysosomal changes and Beclin 1-mediated autophagic cell death. Cell Death and Differentiation 2005, 12(10):1297-1309. Epub 2005/05/21.
77. Hsu J.W., Yasmin-Karim S., King M.R., Wojciechowski J.C., Mickelsen D., Blair M.L., et al. Suppression of prostate cancer cell rolling and adhesion to endothelium by 1alpha,25-dihydroxyvitamin D3. The American Journal of Pathology 2011, 178(2):872-880. Epub 2011/02/02.
78. Ikeda N., Uemura H., Ishiguro H., Hori M., Hosaka M., Kyo S., et al. Combination treatment with 1alpha,25-dihydroxyvitamin D3 and 9-cis-retinoic acid directly inhibits human telomerase reverse transcriptase transcription in prostate cancer cells. Molecular Cancer Therapeutics 2003, 2(8):739-746.
79. Iseki K., Tatsuta M., Uehara H., Iishi H., Yano H., Sakai N., et al. Inhibition of angiogenesis as a mechanism for inhibition by 1alpha-hydroxyvitamin D3 and 1,25-dihydroxyvitamin D3 of colon carcinogenesis induced by azoxymethane in Wistar rats. International Journal of Cancer 1999, 81(5):730-733.
80. Jamshidi F., Zhang J., Harrison J.S., Wang X., Studzinski G.P. Induction of differentiation of human leukemia cells by combinations of COX inhibitors and 1,25-dihydroxyvitamin D3 involves Raf1 but not Erk 1/2 signaling. Cell Cycle 2008, 7(7):917-924.
81. Ji Y., Studzinski G.P. Retinoblastoma protein and CCAAT/enhancer-binding protein beta are required for 1,25-dihydroxyvitamin D3-induced monocytic differentiation of HL60 cells. Cancer Research 2004, 64(1):370-377. Epub 2004/01/20.
82. Jiang F., Bao J., Li P., Nicosia S.V., Bai W. Induction of ovarian cancer cell apoptosis by 1,25-dihydroxyvitamin D3 through the down-regulation of telomerase. The Journal of Biological Chemistry 2004, 279(51):53213-53221.
83. Jiang F., Li P., Fornace A.J., Nicosia S.V., Bai W. G2/M arrest by 1,25-dihydroxyvitamin D3 in ovarian cancer cells mediated through the induction of GADD45 via an exonic enhancer. The Journal of Biological Chemistry 2003, 278(48):48030-48040. Epub 2003/09/25.
84. Kasiappan R., Shen Z., Tse A.K., Jinwal U., Tang J., Lungchukiet P., et al. 1,25-Dihydroxyvitamin D3 suppresses telomerase expression and human cancer growth through microRNA-498. The Journal of Biological Chemistry 2012, 287(49):41297-41309. Epub 2012/10/12.
85. Kawa S., Nikaido T., Aoki Y., Zhai Y., Kumagai T., Furihata K., et al. Vitamin D analogues up-regulate p21 and p27 during growth inhibition of pancreatic cancer cell lines. British Journal of Cancer 1997, 76(7):884-889. Epub 1997/01/01.
86. Kemmochi S., Fujimoto H., Woo G.H., Hirose M., Nishikawa A., Mitsumori K., et al. Preventive effects of calcitriol on the development of capsular invasive carcinomas in a rat two-stage thyroid carcinogenesis model. The Journal of Veterinary Medical Science/The Japanese Society of Veterinary Science 2011, 73(5):655-664. Epub 2011/01/06.
87. Kilkkinen A., Knekt P., Heliovaara M., Rissanen H., Marniemi J., Hakulinen T., et al. Vitamin D status and the risk of lung cancer: A cohort study in Finland. Cancer Epidemiology, Biomarkers & Prevention: A Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology 2008, 17(11):3274-3278.
88. Koli K., Keski-Oja J. 1,25-Dihydroxyvitamin D3 enhances the expression of transforming growth factor beta 1 and its latent form binding protein in cultured breast carcinoma cells. Cancer Research 1995, 55(7):1540-1546. Epub 1995/04/01.
89. Koshizuka K., Koike M., Asou H., Cho S.K., Stephen T., Rude R.K., et al. Combined effect of vitamin D3 analogs and paclitaxel on the growth of MCF-7 breast cancer cells in vivo. Breast Cancer Research and Treatment 1999, 53(2):113-120.
90. Krishnan A.V., Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annual Review of Pharmacology and Toxicology 2011, 51:311-336. Epub 2010/10/13.
91. Krishnan A.V., Swami S., Peng L., Wang J., Moreno J., Feldman D. Tissue-selective regulation of aromatase expression by calcitriol: Implications for breast cancer therapy. Endocrinology 2010, 151(1):32-42. Epub 2009/11/13.
92. Kulkarni A.D., van Ginkel P.R., Darjatmoko S.R., Lindstrom M.J., Albert D.M. Use of combination therapy with cisplatin and calcitriol in the treatment of Y-79 human retinoblastoma xenograft model. The British Journal of Ophthalmology 2009, 93(8):1105-1108.
93. Kundu R., Chain B.M., Coussens A.K., Khoo B., Noursadeghi M. Regulation of CYP27B1 and CYP24A1 hydroxylases limits cell-autonomous activation of vitamin D in dendritic cells. European Journal of Immunology 2014, 44(6):1781-1790. Epub 2014/03/20.
94. Lambert J.R., Eddy V.J., Young C.D., Persons K.S., Sarkar S., Kelly J.A., et al. A vitamin D receptor-alkylating derivative of 1alpha,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growth. Cancer Prevention Research (Philadelphia, PA) 2010, 3(12):1596-1607. Epub 2010/12/15.
95. Lappe J.M., Travers-Gustafson D., Davies K.M., Recker R.R., Heaney R.P. Vitamin D and calcium supplementation reduces cancer risk: Results of a randomized trial. The American Journal of Clinical Nutrition 2007, 85(6):1586-1591. Epub 2007/06/09.
96. Lazzaro G., Agadir A., Qing W., Poria M., Mehta R.R., Moriarty R.M., et al. Induction of differentiation by 1alpha-hydroxyvitamin D(5) in T47D human breast cancer cells and its interaction with vitamin D receptors. European Journal of Cancer 2000, 36(6):780-786. Epub 2000/04/14.
97. Lin R., Amizuka N., Sasaki T., Aarts M.M., Ozawa H., Goltzman D., et al. 1Alpha,25-dihydroxyvitamin D3 promotes vascularization of the chondro-osseous junction by stimulating expression of vascular endothelial growth factor and matrix metalloproteinase 9. Journal of Bone and Mineral Research 2002, 17(9):1604-1612.
98. Liu W., Asa S.L., Ezzat S. 1Alpha,25-dihydroxyvitamin D3 targets PTEN-dependent fibronectin expression to restore thyroid cancer cell adhesiveness. Molecular Endocrinology 2005, 19(9):2349-2357.
99. Liu W., Asa S.L., Fantus I.G., Walfish P.G., Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. The American Journal of Pathology 2002, 160(2):511-519. Epub 2002/02/13.
100. Liu G., Hu X., Chakrabarty S. Vitamin D mediates its action in human colon carcinoma cells in a calcium-sensing receptor-dependent manner: Downregulates malignant cell behavior and the expression of thymidylate synthase and survivin and promotes cellular sensitivity to 5-FU. International Journal of Cancer 2010, 126(3):631-639.
101. Liu M., Lee M.H., Cohen M., Bommakanti M., Freedman L.P. Transcriptional activation of the Cdk inhibitor p21 by vitamin D3 leads to the induced differentiation of the myelomonocytic cell line U937. Genes & Development 1996, 10(2):142-153. Epub 1996/01/15.
102. Ly L.H., Zhao X.Y., Holloway L., Feldman D. Liarozole acts synergistically with 1alpha,25-dihydroxyvitamin D3 to inhibit growth of DU 145 human prostate cancer cells by blocking 24-hydroxylase activity. Endocrinology 1999, 140(5):2071-2076.
103. Ma Y., Liu H., Tu-Rapp H., Thiesen H.J., Ibrahim S.M., Cole S.M., et al. Fas ligation on macrophages enhances IL-1R1-Toll-like receptor 4 signaling and promotes chronic inflammation. Nature Immunology 2004, 5(4):380-387.
104. Ma Y., Yu W.D., Hershberger P.A., Flynn G., Kong R.X., Trump D.L., et al. 1Alpha,25-dihydroxyvitamin D3 potentiates cisplatin antitumor activity by p73 induction in a squamous cell carcinoma model. Molecular Cancer Therapeutics 2008, 7(9):3047-3055.
105. Ma Y., Yu W.D., Su B., Seshadri M., Luo W., Trump D.L., et al. Regulation of motility, invasion, and metastatic potential of squamous cell carcinoma by 1alpha,25-dihydroxycholecalciferol. Cancer 2013, 119(3):563-574. Epub 2012/07/27.
106. Ma Y., Yu W.D., Trump D.L., Johnson C.S. 1,25D(3) enhances antitumor activity of gemcitabine and cisplatin in human bladder cancer models. Cancer 2010, 116(13):3294-3303.
107. Maalmi H., Ordonez-Mena J.M., Schottker B., Brenner H. Serum 25-hydroxyvitamin D levels and survival in colorectal and breast cancer patients: Systematic review and meta-analysis of prospective cohort studies. European Journal of Cancer 2014, 50(8):1510-1521. Epub 2014/03/04.
108. Majewski S., Skopinska M., Marczak M., Szmurlo A., Bollag W., Jablonska S. Vitamin D3 is a potent inhibitor of tumor cell-induced angiogenesis. The Journal of Investigative Dermatology. Symposium Proceedings 1996, 1(1):97-101.
109. Majewski S., Szmurlo A., Marczak M., Jablonska S., Bollag W. Inhibition of tumor cell-induced angiogenesis by retinoids, 1,25-dihydroxyvitamin D3 and their combination. Cancer Letters 1993, 75(1):35-39.
110. Makishima M., Okabe-Kado J., Honma Y. Growth inhibition and differentiation induction in human monoblastic leukaemia cells by 1alpha-hydroxyvitamin D derivatives and their enhancement by combination with hydroxyurea. British Journal of Cancer 1998, 77(1):33-39.
111. Mantell D.J., Owens P.E., Bundred N.J., Mawer E.B., Canfield A.E. 1 Alpha,25-dihydroxyvitamin D(3) inhibits angiogenesis in vitro and in vivo. Circulation Research 2000, 87(3):214-220.
112. Marcinkowska E., Garay E., Gocek E., Chrobak A., Wang X., Studzinski G.P. Regulation of C/EBPbeta isoforms by MAPK pathways in HL60 cells induced to differentiate by 1,25-dihydroxyvitamin D3. Experimental Cell Research 2006, 312(11):2054-2065. Epub 2006/04/21.
113. Mathiasen I.S., Sergeev I.N., Bastholm L., Elling F., Norman A.W., Jaattela M. Calcium and calpain as key mediators of apoptosis-like death induced by vitamin D compounds in breast cancer cells. The Journal of Biological Chemistry 2002, 277(34):30738-30745.
114. Mazzilli S.A., Hershberger P.A., Reid M.E., Bogner P.N., Atwood K., Trump D.L., et al. Vitamin D repletion reduces the progression of premalignant squamous lesions in the NTCU lung squamous cell carcinoma mouse model. Cancer Prevention Research (Philadelphia, PA) 2015, 8(10):895-904. Epub 2015/08/16.
115. McGuire T.F., Trump D.L., Johnson C.S. Vitamin D(3)-induced apoptosis of murine squamous cell carcinoma cells. Selective induction of caspase-dependent MEK cleavage and up-regulation of MEKK-1. The Journal of Biological Chemistry 2001, 276(28):26365-26373.
116. Merke J., Milde P., Lewicka S., Hugel U., Klaus G., Mangelsdorf D.J., et al. Identification and regulation of 1,25-dihydroxyvitamin D3 receptor activity and biosynthesis of 1,25-dihydroxyvitamin D3. Studies in cultured bovine aortic endothelial cells and human dermal capillaries. The Journal of Clinical Investigation 1989, 83(6):1903-1915.
117. Mineva N.D., Wang X., Yang S., Ying H., Xiao Z.X., Holick M.F., et al. Inhibition of RelB by 1,25-dihydroxyvitamin D3 promotes sensitivity of breast cancer cells to radiation. Journal of Cellular Physiology 2009, 220(3):593-599.
118. Moan J., Dahlback A., Lagunova Z., Cicarma E., Porojnicu A.C. Solar radiation, vitamin D and cancer incidence and mortality in Norway. Anticancer Research 2009, 29(9):3501-3509. Epub 2009/08/12.
119. Moffatt K.A., Johannes W.U., Hedlund T.E., Miller G.J. Growth inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) are mediated by increased levels of p21 in the prostatic carcinoma cell line ALVA-31. Cancer Research 2001, 61(19):7122-7129. Epub 2001/10/05.
120. Moffatt K.A., Johannes W.U., Miller G.J. 1Alpha,25dihydroxyvitamin D3 and platinum drugs act synergistically to inhibit the growth of prostate cancer cell lines. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research 1999, 5(3):695-703.
121. Moreno J., Krishnan A.V., Swami S., Nonn L., Peehl D.M., Feldman D. Regulation of prostaglandin metabolism by calcitriol attenuates growth stimulation in prostate cancer cells. Cancer Research 2005, 65(17):7917-7925. Epub 2005/09/06.
122. Muindi J.R., Johnson C.S., Trump D.L., Christy R., Engler K.L., Fakih M.G. A phase I and pharmacokinetics study of intravenous calcitriol in combination with oral dexamethasone and gefitinib in patients with advanced solid tumors. Cancer Chemotherapy and Pharmacology 2009, 65(1):33-40.
123. Muto A., Kizaki M., Yamato K., Kawai Y., Kamata-Matsushita M., Ueno H., et al. 1,25-Dihydroxyvitamin D3 induces differentiation of a retinoic acid-resistant acute promyelocytic leukemia cell line (UF-1) associated with expression of p21(WAF1/CIP1) and p27(KIP1). Blood 1999, 93(7):2225-2233.
124. Nakagawa K., Kawaura A., Kato S., Takeda E., Okano T. 1 Alpha,25-dihydroxyvitamin D(3) is a preventive factor in the metastasis of lung cancer. Carcinogenesis 2005, 26(2):429-440.
125. Nakagawa K., Sasaki Y., Kato S., Kubodera N., Okano T. 22-Oxa-1alpha,25-dihydroxyvitamin D3 inhibits metastasis and angiogenesis in lung cancer. Carcinogenesis 2005, 26(6):1044-1054.
126. Narvaez C.J., Welsh J. Differential effects of 1,25-dihydroxyvitamin D3 and tetradecanoylphorbol acetate on cell cycle and apoptosis of MCF-7 cells and a vitamin D3-resistant variant. Endocrinology 1997, 138(11):4690-4698. Epub 1997/11/05.
127. Narvaez C.J., Welsh J. Role of mitochondria and caspases in vitamin D-mediated apoptosis of MCF-7 breast cancer cells. The Journal of Biological Chemistry 2001, 276(12):9101-9107.
128. Ng K., Meyerhardt J.A., Wu K., Feskanich D., Hollis B.W., Giovannucci E.L., et al. Circulating 25-hydroxyvitamin D levels and survival in patients with colorectal cancer. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2008, 26(18):2984-2991.
129. Nicholas J. Vitamin D, and cancer: Uncertainty persists; research continues. Journal of the National Cancer Institute 2011, 103(11):851-852. Epub 2011/05/25.
130. Niitsu N., Umeda M., Honma Y. Myeloid and monocytoid leukemia cells have different sensitivity to differentiation-inducing activity of deoxyadenosine analogs. Leukemia Research 2000, 24(1):1-9.
131. Nonn L., Peng L., Feldman D., Peehl D.M. Inhibition of p38 by vitamin D reduces interleukin-6 production in normal prostate cells via mitogen-activated protein kinase phosphatase 5: Implications for prostate cancer prevention by vitamin D. Cancer Research 2006, 66(8):4516-4524.
132. Oikawa T., Hirotani K., Ogasawara H., Katayama T., Nakamura O., Iwaguchi T., et al. Inhibition of angiogenesis by vitamin D3 analogues. European Journal of Pharmacology 1990, 178(2):247-250.
133. Okazaki T., Bielawska A., Bell R.M., Hannun Y.A. Role of ceramide as a lipid mediator of 1 alpha,25-dihydroxyvitamin D3-induced HL-60 cell differentiation. The Journal of Biological Chemistry 1990, 265(26):15823-15831. Epub 1990/09/15.
134. Okuda N., Takeda S., Shinomiya K., Muneta T., Itoh S., Noda M., et al. ED-71, a novel vitamin D analog, promotes bone formation and angiogenesis and inhibits bone resorption after bone marrow ablation. Bone 2007, 40(2):281-292.
135. Ooi L.L., Zheng Y., Zhou H., Trivedi T., Conigrave A.D., Seibel M.J., et al. Vitamin D deficiency promotes growth of MCF-7 human breast cancer in a rodent model of osteosclerotic bone metastasis. Bone 2010, 47(4):795-803. Epub 2010/07/20.
136. Ooi L.L., Zhou H., Kalak R., Zheng Y., Conigrave A.D., Seibel M.J., et al. Vitamin D deficiency promotes human breast cancer growth in a murine model of bone metastasis. Cancer Research 2010, 70(5):1835-1844. Epub 2010/02/18.
137. Palmer H.G., Gonzalez-Sancho J.M., Espada J., Berciano M.T., Puig I., Baulida J., et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling. The Journal of Cell Biology 2001, 154(2):369-387.
138. Parise R.A., Egorin M.J., Kanterewicz B., Taimi M., Petkovich M., Lew A.M., et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. International Journal of Cancer 2006, 119(8):1819-1828. Epub 2006/05/19.
139. Peehl D.M., Seto E., Hsu J.Y., Feldman D. Preclinical activity of ketoconazole in combination with calcitriol or the vitamin D analogue EB 1089 in prostate cancer cells. The Journal of Urology 2002, 168(4 Pt. 1):1583-1588.
140. Pendas-Franco N., Garcia J.M., Pena C., Valle N., Palmer H.G., Heinaniemi M., et al. DICKKOPF-4 is induced by TCF/beta-catenin and upregulated in human colon cancer, promotes tumour cell invasion and angiogenesis and is repressed by 1alpha,25-dihydroxyvitamin D3. Oncogene 2008, 27(32):4467-4477.
141. Pendas-Franco N., Gonzalez-Sancho J.M., Suarez Y., Aguilera O., Steinmeyer A., Gamallo C., et al. Vitamin D regulates the phenotype of human breast cancer cells. Differentiation 2007, 75(3):193-207.
142. Peng L., Malloy P.J., Feldman D. Identification of a functional vitamin D response element in the human insulin-like growth factor binding protein-3 promoter. Molecular Endocrinology 2004, 18(5):1109-1119. Epub 2004/02/14.
143. Rashid S.F., Moore J.S., Walker E., Driver P.M., Engel J., Edwards C.E., et al. Synergistic growth inhibition of prostate cancer cells by 1 alpha,25 dihydroxyvitamin D(3) and its 19-nor-hexafluoride analogs in combination with either sodium butyrate or trichostatin A. Oncogene 2001, 20(15):1860-1872.
144. Rassnick K.M., Muindi J.R., Johnson C.S., Balkman C.E., Ramnath N., Yu W.D., et al. In vitro and in vivo evaluation of combined calcitriol and cisplatin in dogs with spontaneously occurring tumors. Cancer Chemotherapy and Pharmacology 2008, 62(5):881-891.
145. Ravid A., Rocker D., Machlenkin A., Rotem C., Hochman A., Kessler-Icekson G., et al. 1,25-Dihydroxyvitamin D3 enhances the susceptibility of breast cancer cells to doxorubicin-induced oxidative damage. Cancer Research 1999, 59(4):862-867.
146. Rebsamen M.C., Sun J., Norman A.W., Liao J.K. 1Alpha,25-dihydroxyvitamin D3 induces vascular smooth muscle cell migration via activation of phosphatidylinositol 3-kinase. Circulation Research 2002, 91(1):17-24.
147. Riachy R., Vandewalle B., Kerr Conte J., Moerman E., Sacchetti P., Lukowiak B., et al. 1,25-dihydroxyvitamin D3 protects RINm5F and human islet cells against cytokine-induced apoptosis: Implication of the antiapoptotic protein A20. Endocrinology 2002, 143(12):4809-4819.
148. Riachy R., Vandewalle B., Moerman E., Belaich S., Lukowiak B., Gmyr V., et al. 1,25-Dihydroxyvitamin D(3) protects human pancreatic islets against cytokine-induced apoptosis via down-regulation of the fas receptor. Apoptosis 2006, 11(2):151-159.
149. Saramaki A., Banwell C.M., Campbell M.J., Carlberg C. Regulation of the human p21(waf1/cip1) gene promoter via multiple binding sites for p53 and the vitamin D3 receptor. Nucleic Acids Research 2006, 34(2):543-554. Epub 2006/01/26.
150. Schottker B., Jorde R., Peasey A., Thorand B., Jansen E.H., Groot L., et al. Vitamin D and mortality: Meta-analysis of individual participant data from a large consortium of cohort studies from Europe and the United States. BMJ 2014, 348:g3656. Epub 2014/06/19.
151. Schwab M., Reynders V., Loitsch S., Steinhilber D., Stein J., Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Molecular Immunology 2007, 44(15):3625-3632. Epub 2007/05/25.
152. Segovia-Mendoza M., Diaz L., Gonzalez-Gonzalez M.E., Martinez-Reza I., Garcia-Quiroz J., Prado-Garcia H., et al. Calcitriol and its analogues enhance the antiproliferative activity of gefitinib in breast cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 2014, 148:122-131. Epub 2014/12/17.
153. Shokravi M.T., Marcus D.M., Alroy J., Egan K., Saornil M.A., Albert D.M. Vitamin D inhibits angiogenesis in transgenic murine retinoblastoma. Investigative Ophthalmology & Visual Science 1995, 36(1):83-87.
154. Slapak C.A., Desforges J.F., Fogaren T., Miller K.B. Treatment of acute myeloid leukemia in the elderly with low-dose cytarabine, hydroxyurea, and calcitriol. American Journal of Hematology 1992, 41(3):178-183.
155. Song X.D., Norman A.W. Bryostatin-1 and 1alpha,25-dihydroxyvitamin D3 synergistically stimulate the differentiation of NB4 acute promyelocytic leukemia cells. Leukemia 1999, 13(2):275-281.
156. Sporn M.B. The war on cancer. Lancet 1996, 347(9012):1377-1381. Epub 1996/05/18.
157. Studzinski G.P., Reddy K.B., Hill H.Z., Bhandal A.K. Potentiation of 1-beta-D-arabinofuranosylcytosine cytotoxicity to HL-60 cells by 1,25-dihydroxyvitamin D3 correlates with reduced rate of maturation of DNA replication intermediates. Cancer Research 1991, 51(13):3451-3455.
158. Sun J., Kong J., Duan Y., Szeto F.L., Liao A., Madara J.L., et al. Increased NF-kappaB activity in fibroblasts lacking the vitamin D receptor. American Journal of Physiology. Endocrinology and Metabolism 2006, 291(2):E315-E322. Epub 2006/03/02.
159. Sung V., Feldman D. 1,25-Dihydroxyvitamin D3 decreases human prostate cancer cell adhesion and migration. Molecular and Cellular Endocrinology 2000, 164(1-2):133-143.
160. Suzuki T., Sano Y., Kinoshita S. Effects of 1alpha,25-dihydroxyvitamin D3 on Langerhans cell migration and corneal neovascularization in mice. Investigative Ophthalmology & Visual Science 2000, 41(1):154-158.
161. Tang J.Y., Fu T., Leblanc E., Manson J.E., Feldman D., Linos E., et al. Calcium plus vitamin D supplementation and the risk of nonmelanoma and melanoma skin cancer: Post hoc analyses of the Women's Health Initiative Randomized Controlled Trial. Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology 2011, 29(22):3078-3084. Epub 2011/06/29.
162. Ting H.J., Hsu J., Bao B.Y., Lee Y.F. Docetaxel-induced growth inhibition and apoptosis in androgen independent prostate cancer cells are enhanced by 1alpha,25-dihydroxyvitamin D3. Cancer Letters 2007, 247(1):122-129.
163. Ting H.J., Messing J., Yasmin-Karim S., Lee Y.F. Identification of microRNA-98 as a therapeutic target inhibiting prostate cancer growth and a biomarker induced by vitamin D. The Journal of Biological Chemistry 2013, 288(1):1-9. Epub 2012/11/29.
164. Trummer O., Langsenlehner U., Krenn-Pilko S., Pieber T.R., Obermayer-Pietsch B., Gerger A., et al. Vitamin D and prostate cancer prognosis: A Mendelian randomization study. World Journal of Urology 2015, Epub 2015/07/26. PMID:. pmid:26209090.
165. Tse A.K., Zhu G.Y., Wan C.K., Shen X.L., Yu Z.L., Fong W.F. 1Alpha,25-dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells. Molecular Immunology 2010, 47(9):1728-1738. Epub 2010/04/08.
166. Upadhyay S.K., Verone A., Shoemaker S., Qin M., Liu S., Campbell M., et al. 1,25-Dihydroxyvitamin D3 (1,25(OH)2D3) signaling capacity and the epithelial-mesenchymal transition in non-small cell lung cancer (NSCLC): Implications for use of 1,25(OH)2D3 in NSCLC treatment. Cancers 2013, 5(4):1504-1521. Epub 2013/11/13.
167. Van Auken M., Buckley D., Ray R., Holick M.F., Baran D.T. Effects of the vitamin D3 analog 1 alpha, 25-dihydroxyvitamin D3-3 beta-bromoacetate on rat osteosarcoma cells: Comparison with 1 alpha, 25-dihydroxyvitamin D3. Journal of Cellular Biochemistry 1996, 63(3):302-310.
168. van der Rhee H., Coebergh J.W., de Vries E. Is prevention of cancer by sun exposure more than just the effect of vitamin D? A systematic review of epidemiological studies. European Journal of Cancer 2013, 49(6):1422-1436. Epub 2012/12/15.
169. Veldman C.M., Cantorna M.T., DeLuca H.F. Expression of 1,25-dihydroxyvitamin D(3) receptor in the immune system. Archives of Biochemistry and Biophysics 2000, 374(2):334-338. Epub 2000/02/10.
170. Vink-van Wijngaarden T., Pols H.A., Buurman C.J., van den Bemd G.J., Dorssers L.C., Birkenhager J.C., et al. Inhibition of breast cancer cell growth by combined treatment with vitamin D3 analogues and tamoxifen. Cancer Research 1994, 54(21):5711-5717.
171. Wactawski-Wende J., Kotchen J.M., Anderson G.L., Assaf A.R., Brunner R.L., O'Sullivan M.J., et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. The New England Journal of Medicine 2006, 354(7):684-696. Epub 2006/02/17.
172. Wang S.H., Koenig R.J., Giordano T.J., Myc A., Thompson N.W., Baker J.R. 1Alpha,25-dihydroxyvitamin D3 up-regulates Bcl-2 expression and protects normal human thyrocytes from programmed cell death. Endocrinology 1999, 140(4):1649-1656.
173. Wang Q., Lee D., Sysounthone V., Chandraratna R.A.S., Christakos S., Korah R., et al. 1,25-Dihydroxyvitamin D3 and retonic acid analogues induce differentiation in breast cancer cells with function- and cell-specific additive effects. Breast Cancer Research and Treatment 2001, 67(2):157-168.
174. Wang X., Rao J., Studzinski G.P. Inhibition of p38 MAP kinase activity up-regulates multiple MAP kinase pathways and potentiates 1,25-dihydroxyvitamin D(3)-induced differentiation of human leukemia HL60 cells. Experimental Cell Research 2000, 258(2):425-437. Epub 2000/07/18.
175. Wang X., Studzinski G.P. Activation of extracellular signal-regulated kinases (ERKs) defines the first phase of 1,25-dihydroxyvitamin D3-induced differentiation of HL60 cells. Journal of Cellular Biochemistry 2001, 80(4):471-482. Epub 2001/02/13.
176. Wang X., Studzinski G.P. Kinase suppressor of RAS (KSR) amplifies the differentiation signal provided by low concentrations 1,25-dihydroxyvitamin D3. Journal of Cellular Physiology 2004, 198(3):333-342. Epub 2004/02/03.
177. Wang Q., Wang X., Studzinski G.P. Jun N-terminal kinase pathway enhances signaling of monocytic differentiation of human leukemia cells induced by 1,25-dihydroxyvitamin D3. Journal of Cellular Biochemistry 2003, 89(6):1087-1101. Epub 2003/08/05.
178. Wang X., Wang T.T., White J.H., Studzinski G.P. Induction of kinase suppressor of RAS-1(KSR-1) gene by 1, alpha25-dihydroxyvitamin D3 in human leukemia HL60 cells through a vitamin D response element in the 5'-flanking region. Oncogene 2006, 25(53):7078-7085. Epub 2006/05/30.
179. Wang Q., Yang W., Uytingco M.S., Christakos S., Wieder R. 1,25-Dihydroxyvitamin D3 and all-trans-retinoic acid sensitize breast cancer cells to chemotherapy-induced cell death. Cancer Research 2000, 60(7):2040-2048.
180. Webb P.M., de Fazio A., Protani M.M., Ibiebele T.I., Nagle C.M., Brand A.H., et al. Circulating 25-hydroxyvitamin D and survival in women with ovarian cancer. The American Journal of Clinical Nutrition 2015, 102(1):109-114. Epub 2015/05/15.
181. Welsh J. Cellular and molecular effects of vitamin D on carcinogenesis. Archives of Biochemistry and Biophysics 2012, 523(1):107-114. Epub 2011/11/17.
182. Wu G., Fan R.S., Li W., Srinivas V., Brattain M.G. Regulation of transforming growth factor-beta type II receptor expression in human breast cancer MCF-7 cells by vitamin D3 and its analogues. The Journal of Biological Chemistry 1998, 273(13):7749-7756. Epub 1998/04/29.
183. Yee S.W., Campbell M.J., Simons C. Inhibition of vitamin D3 metabolism enhances VDR signalling in androgen-independent prostate cancer cells. The Journal of Steroid Biochemistry and Molecular Biology 2006, 98(4-5):228-235. Epub 2006/02/18.
184. Yin L., Ordonez-Mena J.M., Chen T., Schottker B., Arndt V., Brenner H. Circulating 25-hydroxyvitamin D serum concentration and total cancer incidence and mortality: A systematic review and meta-analysis. Preventive Medicine 2013, 57(6):753-764. Epub 2013/09/17.
185. Young M.R., Halpin J., Hussain R., Lozano Y., Djordjevic A., Devata S., et al. Inhibition of tumor production of granulocyte-macrophage colony-stimulating factor by 1 alpha, 25-dihydroxyvitamin D3 reduces tumor motility and metastasis. Invasion & Metastasis 1993, 13(4):169-177.
186. Young M.R., Lozano Y. Inhibition of tumor invasiveness by 1alpha,25-dihydroxyvitamin D3 coupled to a decline in protein kinase A activity and an increase in cytoskeletal organization. Clinical & Experimental Metastasis 1997, 15(2):102-110.
187. Yu X.P., Bellido T., Manolagas S.C. Down-regulation of NF-kappa B protein levels in activated human lymphocytes by 1,25-dihydroxyvitamin D3. Proceedings of the National Academy of Sciences of the United States of America 1995, 92(24):10990-10994. Epub 1995/11/21.
188. Yu W.D., McElwain M.C., Modzelewski R.A., Russell D.M., Smith D.C., Trump D.L., et al. Enhancement of 1,25-dihydroxyvitamin D3-mediated antitumor activity with dexamethasone. Journal of the National Cancer Institute 1998, 90(2):134-141.
189. Yudoh K., Matsuno H., Kimura T. 1Alpha,25-dihydroxyvitamin D3 inhibits in vitro invasiveness through the extracellular matrix and in vivo pulmonary metastasis of B16 mouse melanoma. The Journal of Laboratory and Clinical Medicine 1999, 133(2):120-128.
190. Zehnder D., Bland R., Chana R.S., Wheeler D.C., Howie A.J., Williams M.C., et al. Synthesis of 1,25-dihydroxyvitamin D(3) by human endothelial cells is regulated by inflammatory cytokines: A novel autocrine determinant of vascular cell adhesion. Journal of the American Society of Nephrology 2002, 13(3):621-629.
191. Zhang Q., Kanterewicz B., Buch S., Petkovich M., Parise R., Beumer J., et al. CYP24 inhibition preserves 1alpha,25-dihydroxyvitamin D(3) anti-proliferative signaling in lung cancer cells. Molecular and Cellular Endocrinology 2012, 355(1):153-161. Epub 2012/03/06.
192. Zheng Y., Zhou H., Ooi L.L., Snir A.D., Dunstan C.R., Seibel M.J. Vitamin D deficiency promotes prostate cancer growth in bone. Prostate 2011, 71(9):1012-1021. Epub 2011/05/05.